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• Time-sensitive access to unapproved experimental interventions should be permitted on
humanitarian grounds when patients or communities are facing death or irreversible
disease progression and no other efficacious diagnostic, preventive, or therapeutic
alternative exists.
• Regulatory deficits could stymie time-sensitive efforts to contain public health threats
when no efficacious curative, therapeutic, or preventive interventions exist to counter
the threat in question.
• United States regulatory mechanisms may provide useful guidance from a regulatory
perspective to policy makers grappling with how to adequately prepare for, or respond
to, potential or emerging public health emergencies.
• Access to unapproved experimental interventions should be underpinned by a robust
monitoring and evaluation component that will inform product development
and licensure.
• A global-level rapid-response governance framework for the employment of unap-
proved interventions in humanitarian contexts should be established as a matter
of urgency.
The rampant spread of the Ebola virus in West Africa has prompted the World Health Organi-
zation (WHO) to declare the outbreak there a public health emergency of international con-
cern [1]. The United Nation’s Ebola Emergency Response Mission’s (UNMEER)
announcement that it would miss its December 2014 deadline to contain the epidemic because
of rising numbers of cases [2] illustrates that in the absence of a proven cure, efficacious treat-
ment options or preventive vaccines for stemming Ebola’s spread in Africa and beyond will de-
pend on several factors, including locating, isolating, and caring for those infected with Ebola,
tracing their contacts, educating affected communities on safe burial practices, and strict ad-
herence to infection control measures [1,3]. The prioritised, accelerated provision of the unap-
proved investigational drug Z-Mapp to selected infected individuals and apparent cures in
some instances as a result thereof highlight that arresting Ebola’s spread may, by necessity, also
have to centre on the accelerated provision of experimental drugs, biological products
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(including vaccines and biological therapeutics), and devices (including in vitro diagnostics) to
affected countries when no adequate, approved, and available alternative to the emergency use
of the products in question exists. Such provision must be underpinned by a robust monitoring
and evaluation component so that the provision can inform future use and policy on the issue.
While this strategy has won WHO endorsement [4], many countries bar the use of unapproved
interventions on humans outside of a clinical trial context and lack appropriate regulatory re-
gimes to facilitate the fast-tracked provision of unapproved interventions to those who need
them. Also currently lacking at a global level is a coordinating rapid response framework for
the employment of unapproved interventions in humanitarian emergencies. In light of this
shortcoming, crucial regulatory-related developments in the aftermath of the West African
Ebola epidemic are welcomed. These include the US Federal Drug Administration’s (FDA) es-
tablishment of an Ebola task force with wide representation from across the FDA to coordinate
its Ebola-related activities [5] and a cooperation pledge by members of an interim International
Coalition of Medicines Regulatory Authorities in August 2014 [6]. Such initiatives must, how-
ever, result in comprehensive, harmonised regulatory mechanisms to ensure that a wide-range
of potential Ebola-related interventions are permissible for use in clinical trial and post-
trial contexts.
The Utility of Comprehensive Regulatory Mechanisms to Address
Public Health Emergencies
TheWHO has urged regulatory authorities to consider the most efficient paths to bring experi-
mental and unapproved products to registration [7]. However, most countries lack regulatory
frameworks that permit the use of unapproved interventions on humans outside of systematic
research conditions (including in “compassionate use” circumstances) and lack reciprocal rec-
ognition agreements with major regulatory agencies, such as the US FDA and the European
Medicines Agency (EMA), both of which permit use of such interventions in prescribed cir-
cumstances. Such regulatory deficits could stymie time-sensitive efforts to contain public
health threats when no efficacious curative, therapeutic, or preventive interventions exist to
counter the threat in question. When no other efficacious intervention exists, national authori-
ties globally have an ethical duty to create enabling regulatory frameworks to facilitate the ac-
celerated provision of unapproved investigational interventions in humanitarian contexts to
those who may derive benefit therefrom. In settings in which national authorities lack the ca-
pacity to devise and enforce such mechanisms, regional structures, such as the African Union
(AU), should take an early lead in devising model regulatory templates for countries to adopt.
A pledge by African authorities at a meeting of the WHO-led African Vaccine Regulatory
Forum (AVAREF) in Pretoria, South Africa, to establish a collaborative mechanism for fast
tracking approvals for clinical trials and registration of Ebola-related products in affected coun-
tries [8] is thus welcome. The utility of prospectively having such mechanisms in place in the
context of public health emergencies is evident in the US, which offers a range of existing regu-
latory access pathways, including under the country’s medical countermeasure development,
preparedness, and response initiative. Some of these regulatory mechanisms are now being
postulated and utilised to facilitate time-sensitive access to investigational interventions in
Ebola-affected countries. These include (a) the use of unapproved drugs through the Emergen-
cy Use Investigational New Drug regulatory pathway and the Emergency Use Authorisation
regulatory pathway, (b) the use of approved drugs for unindicated uses, (c) the partial lifting of
suspended or halted clinical trials involving investigational drugs, and (d) the approval of new
interventions when human efficacy studies are not ethical or feasible. An overview of these
mechanisms may provide useful guidance to policy makers grappling with how to adequately
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prepare for, or respond to, potential or emerging public health emergencies from a
regulatory perspective.
Facilitating Time-Sensitive Access to Unapproved Interventions through
the Use of an Emergency Use Investigational New Drug Regulatory
Pathway
The US regulatory system permits expanded access to or “compassionate use” of an investiga-
tional drug outside of a clinical trial to treat patients with a serious or immediately life-
threatening disease or condition that has no comparable or satisfactory alternative treatment
option. Access to unapproved interventions under such circumstances may occur through an
Emergency Use Investigational New Drug (IND) application or a Treatment Use IND applica-
tion. In the US, “emergency use” is defined as the use of an investigational drug or biological
product with a human subject in a life-threatening situation in which no standard acceptable
treatment is available and in which there is not sufficient time to obtain Institutional Research
Board (IRB) approval [9]. The Emergency Use IND mechanism allows the FDA to authorize
the use of an experimental drug in an emergency situation that does not allow time for submis-
sion of an IND application in accordance with standard regulations [10]. It is a mechanism
that is also used in instances when patients do not meet the criteria of an existing study proto-
col or an approved study protocol does not exist. The mechanism exempts the use of the exper-
imental intervention from prior IRB review and approval, provided that such emergency use is
reported to the IRB within five working days after the use [11]. This mechanism allows for one
emergency use of an experimental intervention at an institution, and any other subsequent use
of the investigational product at the institution is subject to prospective IRB review and ap-
proval [11]. The use of such a mechanism is invaluable in time-sensitive emergencies such as
Ebola outbreaks and was likely the regulatory mechanism utilised to provide the investigational
drug Z-Mapp to two Ebola-infected Americans in Liberia [12].
Facilitating the Time-Sensitive Provision of Investigational Interventions
through Emergency Use Authorisations
In the US, the Emergency Use IND mechanism can generally be used in an emergency situa-
tion for an individual patient. However, the mechanism is ill-suited for use in mass public
health administration—for example, in a universal vaccination campaign against a life-
threatening infectious disease taking place in the context of a national emergency or potential
national emergency [13]. To manage such instances, the US has established a regulatory mech-
anism that permits the FDA to approve the emergency use of drugs, devices, and medical prod-
ucts (including diagnostics) that were not previously approved, cleared, or licensed by the FDA
or the off-label use of approved products in certain well-defined emergency situations [13].
Such authorisation is issued if no adequate, approved, and available alternative to the emergen-
cy use of the product in question exists [14] and if (1) the disease or condition is deemed seri-
ous or life-threatening, (2) the totality of scientific evidence reasonably indicates that the
product in question may be effective, and (3) the known and potential benefits of the product
outweighs its known and potential risks. Such an order was issued for the emergency use of
Oseltamivir (Tamiflu), Zanamivir (Relenza), and Peramivir for the treatment and prophylaxis
of the 2009 H1N1 influenza virus [14]. Similarly in 2005, an Emergency Use Authorization
(EUA) was issued for the emergency use of an unapproved anthrax vaccine for the prevention
of inhalation anthrax [15], because it was believed that US military forces faced a heightened
risk of attack with anthrax. EUA has also previously been used in the context of potential emer-
gencies for the authorisation of experimental diagnostics for the 2013 coronavirus and the
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2013 H7N9 influenza [16]. Such authorisations could be deemed ethically permissible on utili-
tarian and public health ethics grounds. The value of such a mechanism in the context of Ebola
diagnostics was underscored in August 2014. Following an earlier determination in 2006 by the
US secretary of homeland security that Ebola virus presents a material threat to the US popula-
tion sufficient to affect national security [17], on 4 August 2014, the US secretary for health
and human services declared that circumstances existed that justified authorizing the emergen-
cy use of in vitro diagnostics for the detection of Ebola virus [17]. On the basis of this decision,
on 5 August 2014, the US FDA commissioner issued an EUA for the US Department of De-
fense (DoD) Ebola Zaire Target 1 (EZ1) real-time reverse transcription PCR (RT-PCR) assay
for the presumptive detection of Ebola Zaire virus [18].
Facilitating the Time-Sensitive Provision of Interventions through the
Use of Approved Drugs for Unindicated Uses
The off-label use of approved drugs is not equivalent to research or investigational or experi-
mental treatment [19]. Despite the use of approved drugs for unindicated uses being a common
and necessary practice in most settings, it is a practice that is not formally regulated, nor for-
mally condoned, in many settings. The US FDA, however, has attempted to clarify the legitima-
cy of this practice by explicitly condoning the use of approved drugs for unindicated uses in
prescribed circumstances. The FDA has noted that “once a [drug] product has been approved
for marketing, a physician may prescribe it for uses or in treatment regimens or patient popula-
tions that are not included in approved labeling” and that “unapproved” or “unlabeled” uses
may be appropriate and rational in certain circumstances [20]. Given this regulatory permissi-
bility, some US scientists have postulated using drugs that have already been approved for the
treatment of other diseases for the treatment of Ebola [21]. They argue that unlike experimen-
tal Ebola treatments, immunomodulatory drugs have already been approved (thus obviating
the need for safety studies), are currently being produced as inexpensive generics, and are avail-
able even to countries with basic health care systems. While this proposal has yet to win WHO
endorsement, it illustrates the value of having a regulatory regime that permits off-label clinical
use outside of an EUA directive. Such an approach may allow for the use of the anti-influenza
drug Favipiravir (T-705) as an emergency off-label anti-Ebola agent [22], as is currently the
case in France [23], notwithstanding its planned testing as an anti-Ebola agent under clinical
trial conditions.
Facilitating the Time-Sensitive Provision of Investigational Interventions
through the Partial Lifting of Suspended or Halted Clinical Trials
The US regulatory system permits the partial lifting of suspended or halted clinical trials [24].
In such instances, the FDA has the discretion to partially lift a trial’s previously declared “hold”
in prescribed circumstances. Such a mechanism avoids an “all-or-nothing” approach and per-
mits the clinical trial of an investigational agent to proceed under prescribed conditions, which
is invaluable in the context of time-sensitive public health emergencies. The utility of this
mechanism is best illustrated in relation to the clinical trial of the anti-Ebola investigational
drug TKM-Ebola; the drug was approved for testing in a Phase I clinical trial in 2011 [25], but
the trial was then put on hold in early July 2014 to investigate the mechanism behind elevated
cytokines in healthy human volunteers receiving the drug [26]. The FDA’s change of status of
the drug trial to “partial hold” in August 2014 opened up the possibility for administration to
Ebola-infected patients of single ascending doses of the drug, which has demonstrated toler-
ance in the absence of any steroid-containing premedication at a dose level of 0.3 mg/kg, the
maximum tolerated dose in the absence of steroid cover [27].
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Facilitating the Time-Sensitive Use of Investigational Drug Products
When Human Efficacy Studies Are Not Ethical or Feasible
The US FDA has the authority to permit the use of drug products in instances when human effica-
cy studies are not ethical or feasible [28]. In granting such authorisation, the FDAmay grant mar-
keting approval for a new drug product for which safety has been established based on adequate
and well-controlled animal studies, when the results of those animal studies establish that the drug
product is reasonably likely to produce clinical benefit in humans [29]. In assessing the adequacy
of animal data, the FDAmay take into account other data, including available human data. This
mechanism allows the FDA to approve drugs based on efficacy testing in animals and only safety
testing in healthy humans. Such a mechanism is particularly valuable in the context of public
health emergencies in which following a traditional phased clinical trial evaluative process before a
drug can be prescribed for humans is impractical and unfeasible. In 2012 the FDA used its “Ani-
mal Rule”mechanism to approve raxibacumab injections for the treatment of inhalational anthrax
[30]. This regulatory mechanism has been postulated for use in the context of the Ebola outbreaks
[31] and is finding application in respect to the investigational agent BCX4430, which has demon-
strated post-exposure efficacy against Ebola virus andMarburg virus disease in rodent models [32]
and will soon be the subject of a dose ranging efficacy study in nonhuman primates [33].
Addressing Governance Gaps
While AVAREC’s pledged collaborative mechanism for fast tracking approvals of clinical trials
and the registration of trial products in African countries is welcomed, there is currently no
rapid-response governance framework for the employment of unapproved interventions in hu-
manitarian contexts at a global level. Such a system should be created as a matter of urgency.
Crucial to such a system will be the development of harmonized data requirements, which will
allow for the collection of interpretable data.
However, while time-sensitive access to unapproved experimental interventions should be per-
mitted on humanitarian grounds when patients or communities are facing death or irreversible dis-
ease progression and no other efficacious diagnostic, preventive, or therapeutic alternative exists,
such access should be underpinned by a robust monitoring and evaluation component that will in-
form product development and licensure. While the establishment of a governance system on ac-
cess to unregistered investigational interventions at international, regional, and national levels is
crucial to managing public health emergencies of international concern, such a system will be im-
potent in the absence of competent local regulatory capacity, relevant health system infrastructure,
and adequately trained and occupationally protected researchers and health workers at the grass-
roots level. Uniform import and export regulations as well as civil aviation clearance certification
will require particular attention in relation to the transport of biological specimens, especially in
countries with less resources, which may lack robust mechanisms. Addressing such gaps in Ebola-
affected countries concurrent to intervention provision will entail immersive involvement of inter-
national agencies, such as UNMEER andWHO (through initiatives such as AVAREC), donor
countries, and nongovernmental organisations, such as Médecins Sans Frontières (MSF), who
serve as de facto primary service providers in some humanitarian settings. The eradication of Ebola
will necessitate intensive regional cooperation and a well-considered, systematic introduction of ex-
perimental interventions to affected countries on the part of the international community.
Ethics Considerations
Clinical trials on anti-Ebola agents offer trial participants the possibility of accessing unap-
proved intervention. However, such access raises ethical issues. The introduction of novel
PLOSMedicine | DOI:10.1371/journal.pmed.1001793 February 24, 2015 5 / 8
interventions in affected countries will require a transparent site selection policy. This will en-
sure that potential harms and benefits that could arise from the introduction of novel interven-
tions are fairly distributed between affected countries. A transparent site selection policy will
facilitate timely prospective community engagement, which is critical in settings where locals
distrust authorities and Western medicine. Authorities and investigators will need to ensure
that relevant logistics, support infrastructure, and capacity exist in proposed host settings.
These factors will be crucial to rollout success and in ensuring the integrity of emerging efficacy
data. Investigators must ensure meaningful local scientific collaboration. Investigators and au-
thorities must apply their minds to supply chain logistics, clinical support, and social support
in accordance with human rights and ethical norms. The solicitation of informed consent in re-
lation to the use of unproven interventions on individuals should be given particular attention.
To this end, investigators should give thought to managing instances when eligible patients
lack the ability to provide informed consent autonomously, who should qualify as a surrogate
decision-maker when voluntariness may be vitiated by the patient’s dire circumstances, and
how to mitigate the occurrence of therapeutic and preventive misconceptions in regards to
experimental interventions.
Conclusions
Time-sensitive access to unapproved experimental interventions should be permitted condi-
tionally, on humanitarian grounds. Regulatory deficits could stymie time-sensitive efforts to
contain public health threats when no efficacious curative, therapeutic, or preventive interven-
tions exist to counter the threat in question. A global-level rapid-response governance frame-
work for the employment of unapproved interventions in humanitarian contexts should be
established as a matter of urgency. Enacting such measures now will better prepare us to tackle
public health emergencies of international concern in the future.
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